392 related articles for article (PubMed ID: 23089045)
1. Developmental consequences of the ColQ/MuSK interactions.
Karmouch J; Dobbertin A; Sigoillot S; Legay C
Chem Biol Interact; 2013 Mar; 203(1):287-91. PubMed ID: 23089045
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the C-terminal domain of ColQ in endplate acetylcholinesterase deficiency compromise ColQ-MuSK interaction.
Nakata T; Ito M; Azuma Y; Otsuka K; Noguchi Y; Komaki H; Okumura A; Shiraishi K; Masuda A; Natsume J; Kojima S; Ohno K
Hum Mutat; 2013 Jul; 34(7):997-1004. PubMed ID: 23553736
[TBL] [Abstract][Full Text] [Related]
3. Collagen Q and anti-MuSK autoantibody competitively suppress agrin/LRP4/MuSK signaling.
Otsuka K; Ito M; Ohkawara B; Masuda A; Kawakami Y; Sahashi K; Nishida H; Mabuchi N; Takano A; Engel AG; Ohno K
Sci Rep; 2015 Sep; 5():13928. PubMed ID: 26355076
[TBL] [Abstract][Full Text] [Related]
4. Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis.
Ohno K; Ito M; Kawakami Y; Krejci E; Engel AG
Chem Biol Interact; 2013 Mar; 203(1):335-40. PubMed ID: 22981737
[TBL] [Abstract][Full Text] [Related]
5. MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction.
Cartaud A; Strochlic L; Guerra M; Blanchard B; Lambergeon M; Krejci E; Cartaud J; Legay C
J Cell Biol; 2004 May; 165(4):505-15. PubMed ID: 15159418
[TBL] [Abstract][Full Text] [Related]
6. The collagen ColQ binds to LRP4 and regulates the activation of the Muscle-Specific Kinase-LRP4 receptor complex by agrin at the neuromuscular junction.
Uyen Dao TM; Barbeau S; Messéant J; Della-Gaspera B; Bouceba T; Semprez F; Legay C; Dobbertin A
J Biol Chem; 2023 Aug; 299(8):104962. PubMed ID: 37356721
[TBL] [Abstract][Full Text] [Related]
7. Neuromuscular junction immaturity and muscle atrophy are hallmarks of the ColQ-deficient mouse, a model of congenital myasthenic syndrome with acetylcholinesterase deficiency.
Sigoillot SM; Bourgeois F; Karmouch J; Molgó J; Dobbertin A; Chevalier C; Houlgatte R; Léger J; Legay C
FASEB J; 2016 Jun; 30(6):2382-99. PubMed ID: 26993635
[TBL] [Abstract][Full Text] [Related]
8. COOH-terminal collagen Q (COLQ) mutants causing human deficiency of endplate acetylcholinesterase impair the interaction of ColQ with proteins of the basal lamina.
Arredondo J; Lara M; Ng F; Gochez DA; Lee DC; Logia SP; Nguyen J; Maselli RA
Hum Genet; 2014 May; 133(5):599-616. PubMed ID: 24281389
[TBL] [Abstract][Full Text] [Related]
9. Congenital myasthenic syndromes with acetylcholinesterase deficiency, the pathophysiological mechanisms.
Legay C
Ann N Y Acad Sci; 2018 Feb; 1413(1):104-110. PubMed ID: 29405353
[TBL] [Abstract][Full Text] [Related]
10. ColQ controls postsynaptic differentiation at the neuromuscular junction.
Sigoillot SM; Bourgeois F; Lambergeon M; Strochlic L; Legay C
J Neurosci; 2010 Jan; 30(1):13-23. PubMed ID: 20053883
[TBL] [Abstract][Full Text] [Related]
11. Roles of collagen Q in MuSK antibody-positive myasthenia gravis.
Ohno K; Otsuka K; Ito M
Chem Biol Interact; 2016 Nov; 259(Pt B):266-270. PubMed ID: 27119269
[TBL] [Abstract][Full Text] [Related]
12. Collagen Q is a key player for developing rational therapy for congenital myasthenia and for dissecting the mechanisms of anti-MuSK myasthenia gravis.
Ohno K; Ito M; Kawakami Y; Ohtsuka K
J Mol Neurosci; 2014 Jul; 53(3):359-61. PubMed ID: 24234034
[TBL] [Abstract][Full Text] [Related]
13. Cholinesterases and the basal lamina at vertebrate neuromuscular junctions.
Massoulié J; Millard CB
Curr Opin Pharmacol; 2009 Jun; 9(3):316-25. PubMed ID: 19423392
[TBL] [Abstract][Full Text] [Related]
14. Synaptic basal lamina-associated congenital myasthenic syndromes.
Maselli RA; Arredondo J; Ferns MJ; Wollmann RL
Ann N Y Acad Sci; 2012 Dec; 1275():36-48. PubMed ID: 23278576
[TBL] [Abstract][Full Text] [Related]
15. The synaptic muscle-specific kinase (MuSK) complex: new partners, new functions.
Strochlic L; Cartaud A; Cartaud J
Bioessays; 2005 Nov; 27(11):1129-35. PubMed ID: 16237673
[TBL] [Abstract][Full Text] [Related]
16. Anti-MuSK autoantibodies block binding of collagen Q to MuSK.
Kawakami Y; Ito M; Hirayama M; Sahashi K; Ohkawara B; Masuda A; Nishida H; Mabuchi N; Engel AG; Ohno K
Neurology; 2011 Nov; 77(20):1819-26. PubMed ID: 22013178
[TBL] [Abstract][Full Text] [Related]
17. Protein-anchoring therapy to target extracellular matrix proteins to their physiological destinations.
Ito M; Ohno K
Matrix Biol; 2018 Aug; 68-69():628-636. PubMed ID: 29475025
[TBL] [Abstract][Full Text] [Related]
18. Protein-anchoring strategy for delivering acetylcholinesterase to the neuromuscular junction.
Ito M; Suzuki Y; Okada T; Fukudome T; Yoshimura T; Masuda A; Takeda S; Krejci E; Ohno K
Mol Ther; 2012 Jul; 20(7):1384-92. PubMed ID: 22371845
[TBL] [Abstract][Full Text] [Related]
19. The MuSK activator agrin has a separate role essential for postnatal maintenance of neuromuscular synapses.
Tezuka T; Inoue A; Hoshi T; Weatherbee SD; Burgess RW; Ueta R; Yamanashi Y
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16556-61. PubMed ID: 25368159
[TBL] [Abstract][Full Text] [Related]
20. Targeting acetylcholinesterase to the neuromuscular synapse.
Rotundo RL; Rossi SG; Kimbell LM; Ruiz C; Marrero E
Chem Biol Interact; 2005 Dec; 157-158():15-21. PubMed ID: 16289417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
